three years of appetite threads, summarised so you do not have to read them
Something I keep coming back to: three years of appetite threads, summarised so you do not have to read them. Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision. GIP…
Retitled to distinguish preclinical from clinical, which the original ran together.
Are we talking about receptor affinity or clinical potency?
GIP is the arm people argue about because the biology is genuinely unsettled
Which receptor arm are you attributing that to?
receptor distribution is why the side effects are where they are
receptor distribution is why the side effects are where they are
priya_guerrero is right that mechanism gives direction and not magnitude. Worth pinning.
Do you have the paper, or a summary of it?